Literature DB >> 7679644

The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86.

S Demotz1, C Barbey, G Corradin, A Amoroso, A Lanzavecchia.   

Abstract

The response to tetanus toxoid (TT) was studied in immune donors that carry two alleles of DR5 that differ only at DR beta residue 86: DRB1*1101 (G86, abbreviated 1101) and DRB1*1104 (V86, abbreviated 1104). A large number of TT-specific T cell clones was isolated and the epitopes recognized in association with 1101 and 1104 were mapped. We found that two epitopes (p2 and p32) can be recognized in association with both 1101 and 1104 while three epitopes (p23, p27 and p30) are recognized in association with 1101, but never in association with 1104. The sets of naturally processed self peptides displayed by 1101 and 1104 were characterized using alloreactive T cell clones. We found that all 1104 alloreactive clones recognize both 1104 and 1101, while approximately 30% of the alloreactive 1101 clones fail to recognize 1104. Thus it is apparent that both naturally processed TT and self peptides displayed on 1104 molecules represent a fraction of those displayed on 1101 molecules. The mechanism responsible for this differential presentation was investigated by comparing the capacity of 1101 and 1104 antigen-presenting cells to present TT or synthetic peptides to specific T cells and by measuring the binding of these peptides to DR molecules. Three sets of results suggest that V86 acts as a constraint to the binding of naturally processed peptides: (i) all 1104-restricted or alloreactive T cell clones recognize TT- or allo-epitopes presented by 1101 as well, thus ruling out a major effect of V86 as a residue determining T cell restriction specificity; (ii) presentation of naturally processed peptides correlates in general with the capacity of long synthetic peptides to bind to 1101 or 1104 and (iii) while the naturally processed p30 epitope discriminates between 1101 and 1104, a short synthetic peptide binds equally well to and is comparably recognized in association with both 1101 and 1104. Taken together these results suggest that the natural polymorphism at residue 86 might be a molecular switch that finely tunes the complexity of the peptide collection presented on DR molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679644     DOI: 10.1002/eji.1830230219

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2.

Authors:  A Johnson; R Leke; L Harun; C Ginsberg; J Ngogang; A Stowers; A Saul; I A Quakyi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Comparative molecular and three-dimensional analysis of the peptide-MHC II binding region in both human and Aotus MHC-DRB molecules confirms their usefulness in antimalarial vaccine development.

Authors:  M E Patarroyo; G Cifuentes; J Baquero
Journal:  Immunogenetics       Date:  2006-06-22       Impact factor: 2.846

3.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

4.  A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11.

Authors:  C I Pearson; A M Gautam; I C Rulifson; R S Liblau; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

5.  PRBAM: a new tool to analyze the MHC class I and HLA-DR anchor motifs.

Authors:  Anna Mestre-Ferrer; Erika Scholz; Jepi Humet-Alsius; Iñaki Alvarez
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

6.  Isolation and characterization of new human carrier peptides from two important vaccine immunogens.

Authors:  Paeton L Wantuch; Lina Sun; Rachel K LoPilato; Jarrod J Mousa; Robert S Haltiwanger; Fikri Y Avci
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 3.641

7.  HLA-DRB1 leprogenic motifs in nigerian population groups.

Authors:  G P Uko; L Y Lu; M A Asuquo; D Fici; S Mahan; Z Awdeh; E R Udim; W Ding; U Umana; T Adewole; P A Fraser
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

8.  Processing and presentation of tetanus toxin by antigen-presenting cells from patients with chronic granulomatous disease (CGD) to human specific T cell clones are not impaired.

Authors:  C Barbey; J M Tiercy; N Fairweather; H Niemann; R Seger; G Corradin
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.

Authors:  Sandra Iurescia; Daniela Fioretti; Pasquale Pierimarchi; Emanuela Signori; Manuela Zonfrillo; Giancarlo Tonon; Vito M Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-04-27

10.  MultiRTA: a simple yet reliable method for predicting peptide binding affinities for multiple class II MHC allotypes.

Authors:  Andrew J Bordner; Hans D Mittelmann
Journal:  BMC Bioinformatics       Date:  2010-09-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.